Dermato-Endocrinology最新文献_第3页

Association of Acne Tarda with Endocrinological Disorders 迟发性痤疮与内分泌紊乱的关系

Dermato-Endocrinology Pub Date : 2022-09-28 DOI: 10.3390/dermato2040010

E. Makrantonaki, C. Zouboulis

引用次数: 0

Stratum Corneum Structure and Function Studied by X-ray Diffraction x射线衍射研究角质层的结构和功能

Dermato-Endocrinology Pub Date : 2022-08-30 DOI: 10.3390/dermato2030009

I. Hatta

引用次数: 5

First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature SARS-CoV-2强化疫苗接种后首次发病的红斑糠疹:病例报告及文献回顾

Dermato-Endocrinology Pub Date : 2022-07-07 DOI: 10.3390/dermato2030008

T. Gambichler, C. Scheel, Yousef Arafat, Ekaterina Heinzer, Kathrin Noldes, Zenaida Bulic, S. Boms

{"title":"First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature","authors":"T. Gambichler, C. Scheel, Yousef Arafat, Ekaterina Heinzer, Kathrin Noldes, Zenaida Bulic, S. Boms","doi":"10.3390/dermato2030008","DOIUrl":"https://doi.org/10.3390/dermato2030008","url":null,"abstract":"There is increasing evidence of adverse events associated with the use of COVID-19 vaccines. Here, we report a case of the SARS-CoV-2-vaccination-related onset of pityriasis rubra pilaris (PRP) and provide an analysis of previously reported cases in the medical literature. A 67-year-old male presented with a 1-year history of histopathologically proven PRP that first developed 14 days after receiving a COVID-19 booster vaccination. Skin symptoms improved under ustekinumab medication after unsuccessful previous treatment approaches using systemic corticosteroids, brodalumab, and risankizumab. Among the published cases of post-COVID vaccination PRP, 12 (75%) males and 4 (25%) females were reported. The median age of the reported patients was 59 years. In 10 out of 16 patients (62.5%), PRP was diagnosed after the first vaccine dose, in 4 (25%) after the second dose, and in 2 of 15 patients (12.5%) after the third dose. The median time between COVID-19 vaccination and the onset of PRP was 9.5 days (range: 3–60 days). The majority of patients required systemic treatment, including systemic retinoids and methotrexate. PRP might be a rare adverse event after COVID-19 vaccination, particularly affecting older males. Even though most reported patients with COVID-19-vaccination-related PRP could be successfully treated with PRP standard medications, therapy refractory cases may also occur. Thus, clinicians must be aware of this rare but potentially severe complication.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83898257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Recent Trends in the Integrated Management of Cutaneous Squamous Cell Carcinoma 皮肤鳞状细胞癌综合治疗的最新趋势

Dermato-Endocrinology Pub Date : 2022-06-28 DOI: 10.3390/dermato2030007

P. Naik

引用次数: 1

The Influence of c-Kit and NRAS Mutation on Patients’ Survival in Metastatic Melanoma Receiving Immune Checkpoint Inhibitors and Chemotherapy c-Kit和NRAS突变对接受免疫检查点抑制剂和化疗的转移性黑色素瘤患者生存的影响

Dermato-Endocrinology Pub Date : 2022-06-01 DOI: 10.3390/dermato2020006

Tom Möller, H. Schulze

{"title":"The Influence of c-Kit and NRAS Mutation on Patients’ Survival in Metastatic Melanoma Receiving Immune Checkpoint Inhibitors and Chemotherapy","authors":"Tom Möller, H. Schulze","doi":"10.3390/dermato2020006","DOIUrl":"https://doi.org/10.3390/dermato2020006","url":null,"abstract":"The high metastasis and mortality rates of melanoma in the era of chemotherapy have decreased significantly over the last 10 years. The success is owed largely to the introduction of targeted therapy of oncogenes and immunotherapies, such as checkpoint inhibitors. The aim of the present retrospective, monocentric study is to investigate the impact of chemotherapy or immunotherapy in 550 patients with metastatic melanoma between the years of 2010 and 2019, looking at overall survival while considering BRAF/NRAS/c-KIT mutation status. A total of 17 patients were found to have a c-KIT mutation in exon 11, 13 or 17, including 58.3% with acral lentiginous melanoma, with 53% localized primarily in the lower limbs. In 13.3% of the 231 NRAS-mutated melanomas, primary tumor location was found to be in UV-exposed skin such as on the head and neck, thus about 50% lower than in the 302 patients with wild-type (BRAF-/NRAS-/cKIT-negative) melanoma. Patients with NRAS-mutated melanomas had a significantly lower probability of survival compared to patients with wild-type melanomas, irrespective of the recommendations of the clinical guideline on drug therapy for metastatic melanoma that have been in force since 2010. In contrast to patients with wild-type melanoma who showed a higher probability of survival receiving immune checkpoint inhibitors, the overall survival of patients with NRAS-mutated metastatic melanoma was not more favorable after therapy with immune checkpoint inhibitors compared to chemotherapy treatment.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"112 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81008102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effects of Bifidobacterium animalis subsp. lactis Bl-04 on Skin Wrinkles and Dryness: A Randomized, Triple-Blinded, Placebo-Controlled Clinical Trial 动物双歧杆菌亚种的作用。lactis Bl-04对皮肤皱纹和干燥:一项随机、三盲、安慰剂对照的临床试验

Dermato-Endocrinology Pub Date : 2022-05-18 DOI: 10.3390/dermato2020005

L. Huuskonen, Anna Lyra, Eun-Mee Lee, J. Ryu, Hyunjin Jeong, J. Baek, Youngho Seo, Min-koo Shin, K. Tiihonen, Tommi Pesonen, A. Lauerma, Jenni Reimari, A. Ibarra, H. Anglenius

{"title":"Effects of Bifidobacterium animalis subsp. lactis Bl-04 on Skin Wrinkles and Dryness: A Randomized, Triple-Blinded, Placebo-Controlled Clinical Trial","authors":"L. Huuskonen, Anna Lyra, Eun-Mee Lee, J. Ryu, Hyunjin Jeong, J. Baek, Youngho Seo, Min-koo Shin, K. Tiihonen, Tommi Pesonen, A. Lauerma, Jenni Reimari, A. Ibarra, H. Anglenius","doi":"10.3390/dermato2020005","DOIUrl":"https://doi.org/10.3390/dermato2020005","url":null,"abstract":"The effects of orally consumed probiotics on skin wrinkles and dryness are not fully known. A randomized, placebo-controlled, triple-blinded study was conducted with 148 healthy Korean female volunteers aged between 33 and 60 years, who were administered 1.75 × 109 colony-forming units (CFUs) of Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) (N = 74) or matching placebo (N = 74) for 12 weeks. Facial wrinkles (with 3-dimensional (3D) imaging), skin hydration, transepidermal water loss (TEWL), elasticity, and gloss were assessed at baseline and after every 4 weeks of the intervention. Questionnaire-based subjective evaluations of product efficacy and usability were also analyzed. The consumption of Bl-04 was safe and ameliorated significantly facial skin wrinkle parameters (total wrinkle area and volume, average depth of wrinkles, and arithmetic average roughness (Ra)) versus placebo at 4 weeks, but there were no differences at Week 8 or 12 between groups. Skin hydration, TEWL, elasticity, and gloss were similar between treatment groups, as were the subjective evaluation scores. Oral consumption of Bl-04 indicated promising short-term effects on skin appearance from the winter toward the spring. In future study designs, special attention should be paid to environmental conditions as well as to the skin condition and age of the participants.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81116204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors 免疫检查点抑制剂治疗IV期黑色素瘤患者衍生中性粒细胞与淋巴细胞比率的预后表现

Dermato-Endocrinology Pub Date : 2022-04-08 DOI: 10.3390/dermato2020003

T. Gambichler, Rita Mansour, C. Scheel, Shayda Said, N. Abu Rached, L. Susok

{"title":"Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors","authors":"T. Gambichler, Rita Mansour, C. Scheel, Shayda Said, N. Abu Rached, L. Susok","doi":"10.3390/dermato2020003","DOIUrl":"https://doi.org/10.3390/dermato2020003","url":null,"abstract":"The purpose was to evaluate the prognostic performance of the derived neutrophil–to-lymphocyte ratio (dNLR) in patients with metastatic cutaneous melanoma (CM) treated with immune checkpoint inhibitors (ICI). We retrospectively investigated 41 CM patients with stage IV disease who had the indication for treatment with ICI. dNLR as well as NLR were routinely determined prior to the start of ICI treatment. The dNLR and NLR were calculated as follows: dNLR = absolute neutrophil counts (ANC)/white blood cell count −ANC and NRL = ANC/absolute lymphocyte counts, respectively. Follow-up of the patients was performed in line with current guidelines. In univariate analysis, dNLR (p = 0.027 and p = 0.032) as well as NLR (p = 0.0023 and p = 0.0036) were the only parameters which were significantly associated with the best overall response (BOR) and disease control rate (DCR) on ROC curve analyses. NLR negatively correlated with CM-specific survival (r = −0.32, p = 0.043). CM-specific deaths were significantly associated with the absence of immune-related adverse events (p = 0.043), elevated S100 calcium-binding protein B (S100B) at baseline (p = 0.0006), and dNLR (p = 0.024). In multivariate analyses, NLR was the only significant independent predictor for BOR (p = 0.014; odds ratio: 1.7; and 95% CI 1.11 to 2.61) and DCR (p = 0.019; odds ratio: 1.5; and 95% CI 1.07 to 2.19). Regarding CM-specific death, however, normal baseline S100B was the only significant independent predictor (p = 0.0020; odds ratio: 0.074; and 95% CI 0.014 to 0.38) for survival. Our data demonstrate that baseline NLR seems to be superior to dNLR in the prediction of ICI response in CM patients.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88671174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Hyperpigmented Scleroderma-like Lesions under Combined Pembrolizumab and Pemetrexed Treatment of Non-Small Lung Cancer 联合派姆单抗和培美曲塞治疗非小细胞肺癌的色素沉着硬皮病样病变

Dermato-Endocrinology Pub Date : 2022-03-17 DOI: 10.3390/dermato2010002

T. Gambichler, Yi-Pei Lee, Milan Barras, C. Scheel, L. Susok

{"title":"Hyperpigmented Scleroderma-like Lesions under Combined Pembrolizumab and Pemetrexed Treatment of Non-Small Lung Cancer","authors":"T. Gambichler, Yi-Pei Lee, Milan Barras, C. Scheel, L. Susok","doi":"10.3390/dermato2010002","DOIUrl":"https://doi.org/10.3390/dermato2010002","url":null,"abstract":"Immune checkpoint inhibitors (ICI) and other antineoplastic treatment regimens can trigger cutaneous immune-related adverse events (irAEs). There is a tendency for underreporting of such cases, as cutaneous irAEs are typically perceived as mild and transient. However, more serious cutaneous irAEs can occur which, despite their lower frequency, deserve attention and require specific care. Here, we report a case of extensive hyperpigmented scleroderma-like lesions (SLL) on the lower extremities under combination treatment with pembrolizumab and pemetrexed in a patient with metastatic non-small cell lung cancer. The present case in conjunction with a review of the current literature underscores the potential risk of developing SLL under treatment with anti-PD-1 antibody and/or pemetrexed. Moreover, it is possible that this particular combination treatment synergistically increases the risk of SLL. As a result, more such cases may arise in the future, as ICI/pemetrexed combination treatment might be employed more often. As drug-induced SLL usually require systemic treatment with high dose-corticosteroids, physicians should be aware of SLL as an irAE when cancer patients present with sclerotic and/or fibrotic skin lesions.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"07 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76337133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Augmented and Virtual Reality in Dermatology—Where Do We Stand and What Comes Next? 增强现实和虚拟现实在皮肤病学中的应用——我们的研究进展如何?

Dermato-Endocrinology Pub Date : 2022-01-25 DOI: 10.3390/dermato2010001

M. Bonmarin, S. Läuchli, A. Navarini

引用次数: 1

The Case of a Patient with Limited Systemic Sclerosis and Interstitial Lung Disease Overlapping with Systemic Lupus Erythematosus 局限性系统性硬化症、间质性肺病合并系统性红斑狼疮1例

Dermato-Endocrinology Pub Date : 2021-12-20 DOI: 10.3390/dermato1020009

K. Krawczyk, E. Mazur, Jaromir Kargol, Robert Kijowski, A. Reich

引用次数: 0